The total return over the past 12 months is +429.27% vs. +16.94% for the S&P 500. So far it's up -12.13% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +429.27% | +8.07% | (25.05%) | N/A | N/A | N/A |
| Total Return CAGR | +429.27% | +8.07% | (25.05%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Damora Therapeutics, Inc. (DMRA)
| Year | Start price | End price | DMRA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $23.01 | $20.22 | (12.13%) | +14.51% | (26.64%) |
| 2025 | $4.65 | $23.01 | +394.84% | +17.72% | +377.12% |
| 2024 | $18.00 | $4.65 | (74.17%) | +24.89% | (99.06%) |
| 2023 | $28.75 | $18.00 | (37.39%) | +26.19% | (63.58%) |
| 2022 | $75.75 | $28.75 | (62.05%) | (18.17%) | (43.88%) |
| 2021 | $312.75 | $75.75 | (75.78%) | +28.74% | (104.52%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
